This clinical trial is focused on patients who have experienced a heart attack, medically known as Acute Myocardial Infarction. The study aims to evaluate a modified treatment approach using anti-platelet therapy, which involves medications that help prevent blood clots. The medications being studied include Efient (containing prasugrel), Brilique (containing ticagrelor, also known as AZD6140), Plavix (containing clopidogrel), and Aspirine Protect (containing acetylsalicylic acid, commonly known as aspirin). These medications are used to prevent blood platelets from clumping together, which can help keep blood vessels open after a heart attack.

The purpose of the study is to assess the effectiveness of this modified anti-platelet therapy in patients who have undergone a procedure called complete revascularization. This procedure involves treating not only the blockage that caused the heart attack but also any other significant blockages in the heart’s blood vessels. The study will also involve the use of a Firehawk drug-eluting stent, a small tube inserted into the blood vessels to keep them open, which is coated with a low dose of a drug called rapamycin to help prevent further blockages.

Participants in the study will receive one of the anti-platelet medications or a placebo and will be monitored over a period of time to evaluate the occurrence of any adverse events, such as heart-related complications or bleeding. The study will last for up to 52 weeks, during which the safety and effectiveness of the treatment will be closely observed. The main goal is to determine if the modified therapy is as effective as current treatments in preventing serious health events in patients who have had a heart attack.